The quiet after
the neurological
noise.

Synapse uses a wearable array of 64 dry-contact electrodes to continuously map electrical activity across targeted neural circuits. A closed-loop algorithm identifies pathological oscillatory signatures — the 4–8 Hz tremor-driving activity in the thalamo-cortical loop, for instance — and delivers precisely timed, low-energy neuromodulatory pulses that interrupt the aberrant synchrony without suppressing healthy neural function. Think of it as noise-cancelling headphones for a misfiring circuit, not a volume dial for the whole brain.

Synapse is not currently indicated for patients with: active implanted electronic devices (pacemakers, cochlear implants, intrathecal pumps), scalp wounds or active dermatological conditions at the electrode sites, seizure disorders where EEG-identified triggers are unknown, or pregnancy. Patients with severe cognitive impairment may have difficulty with the calibration protocol. A formal candidacy evaluation with a movement disorder neurologist is required before prescription.

The first session is 90 minutes: 30 minutes for baseline neural mapping, 30 minutes for the titration protocol, and 30 minutes of monitored therapeutic delivery. Subsequent sessions are 45–60 minutes. Most patients complete 3 sessions per week for the first 4 weeks (induction phase), then transition to 1–2 sessions per week for maintenance. Sessions happen in a neurologist's office or certified Synapse therapy center. There is no sedation, no preparation, and patients can drive themselves home.

The Synapse Clinical Portal provides week-over-week neuromodulation response curves for each patient. Therapists see delta-band coherence maps, tremor amplitude indices, and patient-reported outcome scores (QUEST, MIDAS) in a single dashboard. Session data exports to Epic and Cerner via HL7 FHIR. Therapists can flag sessions for neurologist review and adjust stimulation parameters within their scope of practice using the Synapse Therapist Protocol.

Synapse has no withdrawal syndrome and no hardware to remove. When treatment is discontinued, symptoms typically return to pre-treatment baseline over 2–6 weeks as the modulated circuits revert to their prior oscillatory patterns. Some patients — particularly those who completed the full 12-week induction protocol — show sustained benefit for 3–6 months after discontinuation, possibly reflecting neuroplastic reorganization. This is an area of active research.

In our Phase II trial, 3 of 247 patients (1.2%) reported transient worsening of tremor amplitude during the titration phase, which resolved within 48 hours with parameter adjustment. No patient experienced permanent worsening. The closed-loop design includes an automatic safety interrupt that halts stimulation if neural activity exceeds pre-set safety thresholds. Unlike DBS, there is no risk of hardware infection, lead migration, or stimulation-induced dysarthria.